(CercleFinance.com) – GE announces that its Healthcare’s Pharmaceutical Diagnostics business will invest $80 million to increase manufacturing capacity by 30% at its active pharmaceutical ingredients (API) site in Lindesnes, Norway.
The investment – which will create some 100 new jobs – is part of GE Healthcare’s broader commitment to meet future global demand for iodinated contrast media, used in X-ray and CT scan procedures (CT).
GE specifies that iohexol and iodixanol are two principles used as contrast products at more than 100 million doses per year.
The new investment – combined with the recent opening of a new production line, filling and finishing, within the GE Healthcare factory in Cork, Ireland, will enable the production of an additional 30 million doses of these products per year. by 2025.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
